Abstract
Tripartite Motif Containing 11 (TRIM11), an E3 ubiquitin ligase, is identified as a carcinogen causing certain human cancers. However, the specific role of TRIM11 is still uncovered in human osteosarcoma (OS) cells. To explore the role of TRIM11 in OS cells, TRIM11 was induced by silencing and overexpression in OS cells using RNA interference (RNAi) and lentiviral vector, respectively. qRT-PCR and western blot were used to examine the transcription and translation levels of the target gene. Cell count kit-8 (CCK-8) assays were established to analyze cell proliferation. Cell apoptosis ratio was determined via flow cytometry. In our analyses, TRIM11 was suggested to be upregulated, and it functioned as a pro-proliferation and antiapoptosis factor in OS cells. Moreover, the extracellular-signal-regulated kinase 1/2 (ERK1/2) inhibitor PD98059 was used to examine the relationship between TRIM11 and ERK1/2 in OS cells. Results demonstrated that the role of TRIM11 was significantly disrupted by the ERK1/2 inhibitor PD98059. Interestingly, we found TRIM11 overexpression did not affect dual-specificity phosphatase 6 (DUSP6) transcription, but improved its translation in OS cells. Co-immunoprecipitation (Co-IP) analyses revealed that TRIM11 interacted with DUSP6. Importantly, overexpression of TRIM11 enhanced DUSP6 ubiquitination in OS cells. Therefore, TRIM11 might suppress the translation of DUSP6 via improving its ubiquitination. Additionally, TRIM11 silencing in OS cells significantly reduced its tumorigenicity in vivo. Overall, our findings firstly revealed that TRIM11 was an oncogene gene in the growth of OS cells and illustrated its potential function as a target in the treatment of OS.
Highlights
Osteosarcoma (OS) is a most frequent primary malignancy of bone, which is identified by the presence of malignant mesenchymal cells [1]
These findings suggested that Tripartite Motif Containing 11 (TRIM11) was upregulated in OS cells
The Co-IP assay confirmed that TRIM11 interacted with dual-specificity phosphatase 6 (DUSP6) in OS cells (Figure 4(c))
Summary
Osteosarcoma (OS) is a most frequent primary malignancy of bone, which is identified by the presence of malignant mesenchymal cells [1]. OS mainly arises in children and adolescents [2]. Due to the early metastatic potential and highly aggressive nature of OS, the outcome of surgical resection and chemotherapy is far from being satisfactory [3]. Tumor diagnosis and treatments have been greatly improved in recently years, the prognosis of patients with recurrence and metastasis remains poor [4]. The effective biomarkers for OS early diagnosis and prognosis are urgently desired [5]. The molecular mechanism of OS is not fully explored
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have